RxDoctor Payments Data

Michelle Long

Gastroenterology · Boston, MANPI 1194952663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,750 of the $30,320 with a category attached, or 91.5%. Novo Nordisk accounts for 98.6% of it on its own, with 1 other manufacturer making up the rest. 2022 is the largest year on record at $17,933, more than ten times the $411 reported in 2019.

$30,320in general payments, 2019–2025

Across 13 payments — averaging $2332.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$30K
  • Gilead$411
$600,776in research payments, 2019–2025

Across 230 payments — averaging $2612.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$320K
  • Intercept Pharmaceuticals, Inc.$123K
  • Intercept Pharma Europe Ltd.$80K
  • E.r. Squibb & Sons, L.L.C.$32K
  • Astrazeneca UK Limited$20K
  • AbbVie$12K
  • plus $14K from 2 others

What the payments were for

  • Consulting fees$27,75092%
  • Travel & lodging$1,9056%
  • Food & beverage$6652%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$29,909
Gilead2$411

How this compares

$30,320 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →